Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
about
Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases: Effect on Serum Autoantibodies and Inflammatory MediatorsThe emerging role of biotechnological drugs in the treatment of goutThe multifaceted aspects of interstitial lung disease in rheumatoid arthritisTNF inhibitor therapy for rheumatoid arthritisEtanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.The protective antibodies induced by a novel epitope of human TNF-alpha could suppress the development of collagen-induced arthritis.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis.Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-α agents.Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Spinal non-Hodgkin's lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review.Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?Validity of SW982 synovial cell line for studying the drugs against rheumatoid arthritis in fluvastatin-induced apoptosis signaling modelBioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Comparison of the risk of infections in different anti-TNF agents: a meta-analysis.Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designsTargeting the immunogenetic diseases with the appropriate HLA molecular typing: critical appraisal on 2666 patients typed in one single centre.Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis.Infections during treatment with biological agents and possible treatment in clinical practice.Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.The in vitro and in vivo anti-inflammatory activities of alphitonin-4-O-β-D-glucopyranoside.Spinal GABA-B receptor modulates neutrophil recruitment to the knee joint in zymosan-induced arthritis.Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice.
P2860
Q26797089-3061478E-A401-4F5A-9A79-B25211630EDDQ26825459-3EDA1F24-4DD3-40A1-BBA7-7B2C7737C79DQ26861557-C77C55DE-C940-416E-BCB7-260AD2006E68Q28972424-B29A1D8B-0680-434A-A280-C52FA0ECD826Q30009390-0DB7D47D-BFEC-4CA5-BCA3-714A19CBC009Q31021097-23E7F974-2311-45F4-ADE7-74147728F30FQ33527432-4D6974D3-F945-45C8-B853-9A7DE1E912FBQ33881234-B9A0170E-F13B-4AAC-B709-C1E25FC54AC9Q36098311-78D15CC9-3E97-4F72-BC25-D05895F31988Q36686079-6156F34E-A92B-4F94-B95A-B0EB2420AF68Q37501529-4FE72D16-7C89-4434-B85B-EDD174479BC4Q38125245-7784426D-90D7-467E-A66A-6744B8BAEEDDQ38176154-209A0899-D735-4EB8-BE82-4FA47A49E95CQ38202031-32EC2E31-311B-44AC-A7E1-DDDA1412EE3AQ38207759-7E94693B-0E9A-4676-ACAB-42B038937E58Q38392607-06AC1FD2-A242-4D2B-A688-6F009303216CQ38445319-0C186CB4-A14E-40EC-9D19-4408D7240E4EQ38877668-F1F2CC46-F228-4FF0-A48D-04F2F6746D2CQ38993250-794D2F11-3C4A-484C-8279-FB6F9898587BQ40345791-2BFBD02D-0D96-4F87-B738-8348D19F87C6Q40556448-A89996C9-A29E-4102-91E6-97D3E86E6897Q41450339-3E6FF3EB-4F95-4EF3-97D8-D4FD1BE9EC51Q41762617-B24C4998-3F75-4894-9963-B4F818FDE47EQ43066415-7321F847-2181-4F86-98A7-2CDF902B5300Q43420503-0C43E2E5-1D03-463F-BFD9-6877977F5692Q45589559-62E43183-AA5C-4E2B-B1E5-C4E486B2B071Q47693399-BBB99E81-3247-4B57-9758-A9F1C4BC20DDQ50123729-ACD767B6-661D-4FA7-9FDF-160A88907090Q53116757-E82B80CC-279B-459D-A220-D3418D33F327Q53650686-4F80A5D4-AE89-473A-B02B-1B87910A2C01
P2860
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
@en
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
@nl
type
label
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
@en
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
@nl
prefLabel
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
@en
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
@nl
P2093
P50
P1433
P1476
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.
@en
P2093
Antonio Marchesoni
Fabiola Atzeni
Matteo Filippini
Roberto Caporali
Roberto Gorla
P304
P356
10.1016/J.AUTREV.2008.11.003
P577
2008-11-17T00:00:00Z